A retrospective comparison of cyclophosphamide plus antithymocyte globulin with cyclophosphamide plus busulfan as the conditioning regimen for severe aplastic anemia by Ommati, Larissa Veloso Mendes et al.
244
Braz J Med Biol Res 42(3) 2009
 L.V.M. Ommati et al.
www.bjournal.com.br
Brazilian Journal of Medical and Biological Research (2009) 42: 244-250
ISSN 0100-879X
A retrospective comparison of
cyclophosphamide plus antithymocyte
globulin with cyclophosphamide plus
busulfan as the conditioning regimen
for severe aplastic anemia
L.V.M. Ommati1,2, C.A. Rodrigues1, A.R. Silva1, L.P. Silva1, M.L.L.F. Chaufaille1 and
J.S.R. Oliveira1,2
1Disciplina de Hematologia e Hemoterapia, Departamento de Oncologia Clínica e Experimental, Escola
Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brasil
2Serviço de Hematologia e Hemoterapia, Hospital Santa Marcelina, São Paulo, SP, Brasil
Correspondence to: J.S.R. Oliveira, Disciplina de Hematologia e Hemoterapia, EPM, UNIFESP,
R. Botucatu, 740, 3º andar, 040023-900 São Paulo, SP, Brasil
Fax: +55-11-5571-8806. E-mail: josesro@uol.com.br
Allogeneic hematopoietic stem cell transplantation (AHSCT) is the treatment of choice for young patients with severe aplastic
anemia (SAA). The association of antithymocyte globulin (ATG) and cyclophosphamide (CY) is the most frequently used
conditioning regimen for this disease. We performed this retrospective study in order to compare the outcomes of HLA-matched
sibling donor AHSCT in 41 patients with SAA receiving cyclophosphamide plus ATG (ATG-CY, N = 17) or cyclophosphamide
plus busulfan (BU-CY, N = 24). The substitution of BU for ATG was motivated by the high cost of ATG. There were no differences
in the clinical features between the two groups, including age, gender, cytomegalovirus status, ABO match, interval between
diagnosis and transplant, and number of total nucleated cells infused. No differences were observed in the time to neutrophil and
platelet engraftment, or in the risk of veno-occlusive disease and hemorrhage. However, there was a higher risk of mucositis in
the BU-CY group (71 vs 24%, P = 0.004). There were no differences in the incidence of neutrophil and platelet engraftment, acute
and chronic graft-versus-host disease, and transplant-related mortality. There was a higher incidence of late rejection in the
ATG-CY group (41 vs 4%, P = 0.009). Although the ATG-CY group had a longer follow-up (101 months) than the BU-CY group
(67 months, P = 0.04), overall survival was similar between the groups (69 vs 58%, respectively, P = 0.32). We conclude that the
association BU-CY is a feasible option to the conventional ATG-CY regimen in this population.
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Introduction
Allogeneic hematopoietic stem cell transplantation
(AHSCT) is the treatment of choice for young adults with
severe aplastic anemia (SAA) (1-5), with cure ranging from
75 to 80% (5,6) and overall survival at 6 years more than
90% (7).
Many conditioning regimens have been used for SAA
with different associations of cyclophosphamide (CY) (6).
CY plus antithymocyte globulin (ATG) is the most com-
monly used regimen due to a low incidence of graft rejec-
tion and chronic graft-versus-host disease (GVHD). Im-
provement in the overall survival for up to 90% was ob-
served in patients who underwent AHSCT in the first
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months after diagnosis and those who received few blood
transfusions prior to transplant (1,5,6).
The first study reporting the use of busulfan (BU) and
CY in a group of highly transfused patients in Brazil showed
results comparable to those observed with conventional
regimens, resulting in an overall survival rate of 70% (8).
Other Brazilian studies also reported the feasibility of add-
ing a low dose of BU (total dose of 4 mg/kg) to 50 mg·
kg-1·day-1 CY for patients exposed to less than 50 transfu-
sions, with acceptable toxicity (9,10). These issues are
especially important in Brazil because less than 15% of our
patients underwent an AHSCT without prior transfusions
(6). However, the use of ATG in the conditioning regimen
for SAA in Brazil is limited because of its high cost. To the
best of our knowledge there are no studies comparing the
combination BU-CY and ATG-CY in the conditioning regi-
men for SAA.
We conducted this retrospective analysis in order to
compare the main outcomes of human leukocyte antigen
(HLA)-matched related AHSCT for patients with SAA treated
with ATG-CY and BU-CY conditioning regimens.
Patients and Methods
Study group
From November 1993 to January 2007, 41 patients
with SAA underwent an HLA identically matched sibling
donor AHSCT at Hospital São Paulo (14 patients) and
Hospital Santa Marcelina (27 patients). Diagnosis of SAA
was confirmed at admission from the referring center by
the Camitta’s criteria (11).
HLA class I and II typing was performed by serology
and mixed lymphocyte culture before the year 2000, and
then by serology and real-time polymerase chain reaction
(sequence-specific primers and sequence-specific oligo-
nucleotide probes). All patients received bone marrow
stem cells.
All patients or their legal guardians and all donors gave
written informed consent for the AHSCT and the study was
approved by the Ethics Committee of both Hospitals.
Treatment protocol
ATG-CY. Treatment consisted of 50 mg·kg-1·day-1 CY,
iv, from day -5 to day -2, and 30 mg·kg-1·day-1 horse
antithymocyte globulin (UpJohn, USA) from day -4 to day
-2, starting 12 h after the last dose of CY (12).
BU-CY. Treatment consisted of 12 mg/kg BU orally in
16 divided doses of 0.75 mg/kg every 6 h from day -7 to day
-4, and 60 mg·kg-1·day-1 CY, iv, on day -3 and day -2 (13).
The graft was unmanipulated and GVHD prophylaxis con-
sisted of cyclosporin, administered from day -1 to day +420
and then tapered gradually until day +480, and 15 mg/m2
methotrexate administered on day +1, and 10 mg/m2 on
days +3, +6, and +11 (14).
Supportive care
Patients were transplanted in private rooms, equipped
with HEPA filters. Antimicrobial prophylaxis consisted of
trimethoprim-sulfamethoxazole, norfloxacin, fluconazole,
and acyclovir. All blood products were irradiated and leu-
kocyte-depleted in both hospitals.
End-point definitions
Sinusoidal obstruction syndrome was diagnosed ac-
cording to published criteria (15). Incidence of neutrophil
recovery was defined as the first of 3 consecutive days with
a neutrophil count of at least 0.5 x 109/L, while platelet
recovery was defined as the first of 7 consecutive days of
an unsupported platelet count of at least 20 x 109/L. Graft
failure was defined as no sign of neutrophil recovery, as
well as only a transient engraftment of donor cells 28 days
after transplantation. Acute GVHD at day 100 and chronic
GVHD at 5 years was diagnosed and graded according to
published criteria (16), with histopathological confirmation
when possible. Transplant-related mortality (TRM) at 6
months, 1 and 5 years was defined as deaths related to
transplantation and not to relapse.
Chimerism was evaluated by a variable number of
tandem repeats, using 4 primers (Apo-B, D1S80, vWF,
and DXS52), and also by fluorescent in situ hybridization
(FISH), using a double XY probe in sex-mismatched do-
nor-recipient pairs. Chimerism evaluation was performed
retrospectively (at least 1 year after the transplant). Full
donor chimerism was defined as the presence of more
than 99% of the cells of donor origin, mixed chimerism if
more than 1% and less than 99% of donor cells and
autologous recovery if less than 1% of donor cells.
Statistical analysis
Data were analyzed through April 2008. Thus, all sur-
viving patients were followed-up for at least 15 months
after transplant. Cumulative incidence function using death
as a competing event was used to estimate neutrophil and
platelet engraftment, acute and chronic GVHD, rejection
and TRM. The Kaplan-Meier method was used to estimate
overall survival. For continuous variables, the median was
used as the cut-off point. For comparing the groups using
cumulative incidence function, univariate analyses were
performed using Gray’s test (17). For overall survival, log-
rank tests in univariate analyses were used. P values
<0.05 were considered statistically significant. Statistical
analyses were performed with SPSS (SPSS Inc., USA)
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and S-Plus (Insightful Corporation, USA) softwares.
Results
Patient and graft characteristics are shown in Table 1.
Median age was 24 years of age, ranging from 14 to 48
years. There were no differences between the groups in
most clinical features (age, recipient gender, donor gen-
der, cytomegalovirus (CMV) status, ABO match, number
of prior transfusions, time between diagnosis and trans-
plant and number of total nucleated cells infused). In the
ATG-CY group, only 3 (18%) patients were transplanted
after 2000, compared with 19 (79%) in the BU-CY group (P
< 0.0001).
The median number of platelet transfusions prior to the
transplant was higher in the ATG-CY group (53 units) than
in the BU-CY group (13 units, P = 0.06). The number of red
blood cell transfusion appeared to be higher in the ATG-
CY group (20 vs 9 units), but the difference was not
statistically significant (P = 0.53).
Twenty-four (59%) patients were treated for SAA be-
fore transplant: 10 patients received prednisone alone, 13
received prednisone-based associations with cyclosporine
(N = 5), oxymetholone (N = 5), cyclosporine and ATG (N =
2), and cyclosporine and oxymetholone (N = 1). One
patient received oxymetholone alone.
Median follow-up time of survivors was 75.5 months,
ranging from 17 to 152 months. Follow-up was longer for
the ATG-CY group (101 months, ranging from 22 to 152)
than in the BU-CY group (67 months, range 17-107, P =
0.04). The difference was due to the fact that, after 2000,
ATG was no longer available for most patients and we
decided to change the standard protocol to BU-CY.
Engraftment and rejection
Day 30 cumulative incidence of neutrophil recovery
was 82 and 75%, and median time to neutrophil recovery
was 18 (range, 15-27) and 20 days (range, 13-26) in the
ATG-CY and BU-CY groups, respectively (P = 0.22, Table
2).
Six patients died before day +30 without achieving
neutrophil engraftment (4 in the BU-CY group and 2 in the
ATG-CY group). Primary graft failure occurred in 2 pa-
tients, both in the BU-CY group: 1 patient underwent a
second AHSCT from the same donor at day +33, having
received 30 mg·kg-1·day-1 ATG, iv, for 3 days as condition-
ing regimen. The total nucleated cell dose infused was 5.7
x 108/kg in the first transplant and 9.4 x 108/kg in the
second. He failed to engraft again and died at day +56 due
to a pulmonary bacterial infection. The other patient also
underwent a second transplant with the same donor at day
+35 without receiving any preparative regimen. The total
nucleated cell dose was 3.2 and 3.4 x 108/kg in the first and
second infusions, respectively. He developed acute GVHD
and chronic GVHD, and was alive 23 months after the
second transplant.
The 100-day cumulative incidence of platelet engraft-
ment was 82 and 67%, and median time to platelet engraft-
ment was 20 (range, 17-33) and 21 days (range, 14-26), in
the ATG-CY and BU-CY groups, respectively (P = 0.15).
Late rejection occurred in 8 patients. The cumulative
incidence of late rejection at 5 years was 41% in the ATG-
Table 1. Characteristics of patients and grafts.
Characteristics  ATG-CY (N = 17) BU-CY (N = 24)
Age at transplantation in years, median (range) 24 (14-46) 25 (15-48)
Recipient gender, male, N (%) 10 (59%) 14 (58%)
Donor gender, male, N (%) 9 (53%) 9 (38%)
Female donor to a male recipient, N (%) 4 (24%) 7 (29%)
Recipient CMV positive, N (%) 9/12 (75%) 14/18 (78%)
Donor CMV positive, N (%) 7/11 (64%) 13/18 (72%)
ABO match, N (%) 12 (71%) 15 (63%)
Units of red cell transfusions prior to AHSCT, median (range) 20 (0-50) 9 (0-97)
Units of platelet transfusions prior to AHSCT, median (range) 53 (0-180) 13 (0-150)
More than 15 units of red cell transfusions prior to AHSCT 9/16 (56) 6/23 (26)
More than 20 platelet transfusions prior to AHSCT 11/16 (69) 10/23 (44)
Interval diagnosis-transplant in months, median (range) 5 (1-18) 2.5 (1-74)
Number of total nucleated cells, x 108/kg, median (range) 5.1 (2.5-9.8) 4.3 (2.2-7.9)
Follow-up time in months, median (range) 101 (22-152) 67 (17-107)*
ATG-CY = antithymocyte globulin and cyclophosphamide; BU-CY = busulfan and cyclophosphamide; CMV = cytomegalovirus;
AHSCT = allogeneic hematopoietic stem cell transplantation. *P < 0.05 compared to ATG-CY (Student t-test).
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CY group and 4% in the BU-CY group (P = 0.009). A
second transplant was performed in 3 patients: all en-
grafted after the second transplant. However, one patient
had another late graft rejection and died at day +261 from
pulmonary aspergillosis. The other two were still alive with
a follow-up of 38 and 108 months after the 2nd transplant.
The remaining 5 patients were treated with immunosup-
pression. Four had a good response and are still alive at
11, 53, 74, and 81 months after the rejection, and one
patient died due to infection and sepsis at day +790.
Chimerism analysis was performed retrospectively for
16 of 26 (62%) patients who were alive at the time of
assessment. Full donor chimerism was observed in 14
(88%) patients, mixed in one and autologous recovery in
one (late graft rejection). The patient with mixed chimerism
progressed to graft failure shortly after the chimerism
analysis.
Transplant complications
Mucositis occurred more frequently in the BU-CY group
(17 patients, 71%) compared with the ATG-CY group (4
patients, 24%, P = 0.004), as shown in Table 2. The
incidences of veno-occlusive disease (VOD) and hemor-
rhage were similar in both groups.
Positive peripheral blood cultures during febrile epi-
sode were carried out on 10 occasions. In one of them, in
addition to peripheral blood, culture of the central venous
catheter was positive. The pathogens that were isolated
were Escherichia coli, Enterobacter sp, Staphylococcus
coagulase negative, Candida sp (4 cases), Gram-positive
coccus, Corynebacterium sp and Pseudomonas sp. As-
pergillosis was detected in 4 patients; 1 had bone and 3
pulmonary involvement, 2 of them had fatal disease. Bron-
chopneumonia was observed in 9 cases, 5 were fatal.
CMV was diagnosed in 7 cases: positive antigenemia in 5,
and disease in 2 patients, of which one had enteritis and
another interstitial pneumonia CMV infection. Varicella
zoster infection was observed in 4 cases (one of them
presented clinical characteristics of acute abdomen). Pos-
sible cerebral toxoplasmosis was diagnosed by MRI im-
ages in 1 patient.
Graft-versus-host disease
Four patients had acute GVHD grade II and 3 patients
grade III. The 100-day cumulative incidence of grade II to
IV acute GVHD was 6% in the ATG-CY group and 25% in
the BU-CY group (P = 0.11).
Twenty-seven patients were evaluated for chronic
GVHD. The 5-year cumulative incidence was 24% in the
ATG-CY group and 22% in the BU-CY group (P = 0.96).
Chronic GVHD was limited in 6 patients and extensive in 3.
Transplant-related mortality
Fifteen patients (36.6%) died from transplant-related
causes, 5 in the ATG-CY group and 10 in the BU-CY group.
Cumulative incidence of TRM at 5 years was 18% in the
ATG-CY group and 38% in the BU-CY group (P = 0.27).
The principal causes of TRM were infections (N = 9):
bacterial in 7 cases and fungal in 2. The other causes were:
hemorrhage (N = 2), VOD (N = 1), late rejection (N = 1),
chronic GVHD (N = 1), and cardiac toxicity (N = 1).
Overall survival
Probability of overall survival at 5 years was 69% for
the ATG-CY group and 58% for the BU-CY group (P = 0.31,
Figure 1).
Table 2. Main treatment outcomes.
Characteristics ATG-CY (N = 17) BU-CY (N = 24)
Time to neutrophil engraftment, median (range) 18 (15-27) 20 (13-26)
Time to platelet engraftment, median (range) 20 (17-33) 21 (14-26)
Development of mucositis, N (%) 4 (24%) 17 (71%)*
Development of hemorrhage, N (%) 1 (6%) 6 (25%)
Development of VOD, N (%) 1 (6%) 3 (13%)
CI of neutrophil engraftment at 28 days, number of events (%) 15 (82%) 18 (75%)
CI of platelet engraftment at 100 days, number of events (%) 15 (82%) 16 (67%)
CI of acute GVHD at 100 days, number of events (%) 1 (6%) 6 (25%)
CI of chronic GVHD at 5 years, number of events (%) 4 (24%) 5 (22%)
CI of late rejection at 5 years, number of events (%) 7 (41%) 1 (4%)*
CI of transplant-related mortality at 1 year, number of events (%) 4 (24%) 9 (38%)
Probability of overall survival at 5 years, number of events (%) 5 (69%) 10 (58%)
ATG-CY = antithymocyte globulin and cyclophosphamide; BU-CY = busulfan and cyclophosphamide; VOD = veno-occlusive disease;
CI = cumulative incidence; GVHD = graft-versus-host disease. *P < 0.05 compared to ATG-CY (Gray test).
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Discussion
In this retrospective analysis comparing two condition-
ing regimens for SAA, outcomes were similar between
ATG-CY and BU-CY, except for the incidence of mucositis,
which was more frequent with the use of BU, and late
rejection, surprisingly more frequent with the use of ATG
(Table 2).
Since the end of the 1970’s, several marrow transplant
centers have used CY-based conditioning regimens for
SAA (18). At the end of the 1980’s, the Seattle group
started using the association of CY and ATG, which is
currently the most commonly used regimen, with an overall
reduction of rejection rates in less transfused patients (12,
13,18,19). In Brazil, a pilot study showed that the associa-
tion of BU and CY was also feasible in heavily transfused
patients (13), with a rejection rate of 9% and an overall
survival of 70% (8). Since that study, BU-CY has been
used by many Brazilian transplant centers due to its lower
cost than ATG-CY.
In the present study, ATG was initially available for
patients receiving an AHSCT for SAA at both participating
centers, but was no longer available after 2001, when it
was replaced by busulfan. We then decided to conduct this
study in order to compare the main outcomes of the two
regimens.
The main clinical features were similar between the two
groups. The median number of both platelet and red blood
cell transfusions prior to the transplant was higher in the
ATG-CY group but this difference was not statistically
significant. This may explain the higher rates of graft failure
(especially late graft failure) in the ATG group.
Most of the outcomes analyzed were not different
between the two groups of patients. Oral mucositis was
more frequent and severe in the BU-CY group, as was
TRM, probably due to a higher toxicity of BU.
VOD, which is not frequently seen in AHSCT for SAA
(20), was observed in 9.7% of the cases, with one case of
severe VOD in the BU-CY group. There are only a few
reported cases of VOD after AHSCT for SAA and the main
reason for this low incidence might be the use of less toxic
conditioning regimens, usually based on CY alone or in
combination with ATG (20).
Graft rejection decreased in the ATG-CY era, but it is
still frequent, particularly in highly transfused patients (2,5,
10). The number of prior transfusions is associated with
rejection and survival after AHSCT (10), due to the sensi-
tization by the histocompatibility antigens infused with
blood products. In this group, chronic rejection was sur-
prisingly more frequent with the use of ATG than with the
use of BU (P = 0.009). A possible explanation for this
finding is that the ATG group corresponds to transplants
performed before the year 2001, when patients were still
referred for transplant after having frequently been heavily
transfused, and with blood products not leukocyte-de-
pleted in the centers of origin. Leukocyte depletion is
routinely used today. Only one case of late rejection was
observed in patients submitted to the BU conditioning
regimen, which indicates that this regimen is also effica-
cious in promoting sustained engraftment. This conclusion
has been demonstrated in a larger number of patients
conditioned with BU-CY (9). Primary and late graft failures
were demonstrated in 4/139 (3%) and 19/135 (14%), re-
spectively. Therefore, BU-CY should also be considered
as an alternative regimen for highly transfused patients (9).
The cumulative incidence of acute GVHD was higher in
the BU-CY group (25%) than in the ATG-CY group (6%),
but the difference was not statistically significant. The
cumulative incidence of chronic GVHD in the present study
was similar between the ATG-CY and BU-CY regimens
(24 and 22%, respectively), and the majority of patients
responded well to immunosuppression (7). Most cases
were limited (N = 6), and only one patient died from chronic
GVHD. Kröger et al. (19) described an incidence of chronic
GVHD of 17% among patients who underwent an AHSCT
for SAA, and only cases of limited disease were observed.
Data from the WPSAA (Working Party on Severe Aplastic
Anemia) Registry of the EBMT (European Group for Blood
and Marrow Transplantation) show an incidence of chronic
GVHD of 23% in SAA, with an observed reduction of
Figure 1. Estimated overall survival according to the condition-
ing regimen for patients who received the association of antithy-
mocyte globulin and cyclophosphamide (continuous line), or
busulfan and cyclophosphamide (dashed line) after allogeneic
hematopoietic stem cell transplantation for severe aplastic ane-
mia. There was no statistically significant difference between
treatments (log-rank test).
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extensive chronic GVHD of 15% before 1990 to 5% in the
last decade particularly due to the worldwide use of the
CY-ATG association instead of CY plus total body irradia-
tion or thoraco-abdominal irradiation.
Overall survival was slightly higher in the ATG-CY
group (69%) compared to the BU-CY group (58%), but the
difference was not statistically significant. We observed
that early deaths were more frequent, probably due to
toxicity in the BU-CY group. The main cause of death was
infection, which is expected in such a highly immunosup-
pressed population.
The results in the CY-ATG group are consistent with
most previously reported studies, in which overall survival
rates varied between 68 and 80% (5,21,22). More re-
cently, a prospective randomized clinical trial (23,24)
showed that there was no difference between the ATG-CY
association and CY alone for patients with SAA. All ana-
lyzed outcomes (engraftment, GVHD, rejection, and sur-
vival) were similar for the two regimens.
The main limitations of the present study were the
sample size and the fact that the two regimens were used
at different periods of time: ATG-containing regimens were
not used after 2001. Larger series of patients with a more
homogenous group of patients are needed.
BU plus CY is a feasible option in Brazil, due to its
relatively low cost compared with ATG-containing regi-
mens.
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